Jazz Pharmaceuticals

Emerging Therapies And Portfolio Expansion Will Shape Future Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 Aug 24

Updated

20 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

42.3%

7D

4.0%

Loading

1Y

42.3%

7D

4.0%

You can edit this narrative until Nov 21 6:10 AM. Then, changes will post as Updates.

Author's Valuation

US$206.3814.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 20 Nov 25

Fair value Increased 11%

JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology

Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.

Shared on 30 Aug 25

Fair value Increased 1.64%

Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.

Shared on 07 May 25

Fair value Decreased 1.01%

Shared on 30 Apr 25

Fair value Decreased 1.49%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 1.74%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 1.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 0.58%

AnalystConsensusTarget has decreased revenue growth from 5.8% to 5.0%.

AnalystConsensusTarget Fair Value

US$206.38

14.3% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

7.44%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.34%

Calculation

US$964.62m

Earnings '28

x

15.88x

PE Ratio '28

=

US$15.31b

Market Cap '28

US$15.31b

Market Cap '28

/

60.86m

No. shares '28

=

US$251.62

Share Price '28

US$251.62 Share Price '28

Discounted to 2025 @ 7.34% p.a.

=

US$203.45

Fair Value '25